Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Genetic of Skeletal Muscle Insulin Resistance

The University of Texas Health Science Center at San Antonio · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT07780513

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
100
US sites recruiting
1
Study start
August 31, 2026
Record last updated
August 24, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

In this study, the investigators will use euglycemic/hyperinsulinemic clamps, longitudinal skeletal muscle biopsies, and single nucleus ribonucleic acid sequencing (RNA-Seq) and assay for transposase-accessible chromatin using sequencing (ATAC- seq) to reveal cell type-specific molecular response quantitative trait loci (rQTLs) acutely regulated by insulin signaling and glucose uptake.

Being studied: Insulin 80mU/m2*min

Conditions: Insulin Stimulated

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Males and Females Age 18-75
  • Body Mass Index (BMI) > 18
  • Normal glucose tolerance as defined by:

Fasting blood sugar \< 100 mg/dL 2-hour Oral Glucose Tolerance Test (OGTT) \< 140mg/dL Stable weight over the past 3 months defined as >±5% change in body weight

  • Hemoglobin A1c \< 5.7
  • Creatinine \< 2
  • Aspartate aminotransferase/Alanine transaminase (AST/ALT) \< 75
  • Blood sodium 135 to 145 mEq/L
  • Blood potassium 3.6 to 5.2 mmol/L[MH1.1]

Exclusion Criteria

  • Urine albumin excretion>300mg/day
  • Partial thromboplastin time (PTT) >35International normalized ratio (INR) > 1.2
  • No oral corticosteroids for 1 month
  • No Sodium-glucose co-transporter 2 (SGLT2) inhibitor for 3 months
  • No glucagon-like peptide-1 (GLP-1) receptor agonist for 6 months
  • Any anti-platelet or anti-coagulation medication other than as needed for Pain Management
  • No alcohol 4 days before the insulin clamp and biopsy procedure
  • No acute structural knee injuries
  • No Rheumatologic muscular or nervous system disease
  • Pregnancy, Intentions to become pregnant, or Breastfeeding
  • Blood Pressure >170/110
  • Temperature > 100F
  • Triglycerides > 400 by lipid panel
  • Hemoglobin \<10g/dL
  • 1+ or greater Blood on Urinalysis
  • 2+ or greater Protein on Urinalysis
  • Electrocardiogram (EKG) abnormalities, including but not limited to ST elevations, T wave abnormalities, evidence of recent prior infarct

Recruiting US locations

  • Texas Diabetes Institute - University Health System, San Antonio, Texas 78207

    San Antonio, TX 78229

    Site contact: Luke Norton, Ph.D · 210-567-0739 · nortonl@uthscsa.edu

Study contacts (from the official record)

  • Luke Norton, Ph.D · 210-567-0739 · nortonl@uthscsa.edu
All diabetes studies in Texas →
Genetic of Skeletal Muscle Insulin Resistance (NCT07780513) | Bored Studies